Medprin Regenerative Medical Technologies released its 2026 interim report on August 21, 2026. The company's total operating revenue was 190 million yuan, and net profit attributable to the parent company was 56.5805 million yuan. Net cash inflow from operating activities was 48.2026 million yuan, a decrease of 8.3184 million yuan compared with the same period last year, down 14.72 percent year on year. The company's latest asset-liability ratio was 9.97 percent, up 0.29 percentage points from the previous quarter. Gross margin was 78.96 percent, down 1.63 percentage points from the same period last year. The latest return on equity was 6.97 percent, and diluted earnings per share was 0.85 yuan. The company had 8,030 shareholders, and the top ten shareholders held 38.4961 million shares, accounting for 57.41 percent of total share capital.
Medprin Regenerative Medical Technologies Co. Ltd.Company released interim report with net profit of 56.58 million yuan, indicating profitability.
